



Adolore BioTherapeutics Invited to Present at the 16th Annual Pain Therapeutics Summit

Company to discuss its next generation, disease-modifying, non-opioid analgesic gene therapy in development for the treatment of chronic pain

DELRAY BEACH, FL.--November 14, 2022 – [Adolore BioTherapeutics, Inc.](#) (“Adolore” or the “Company”), a biotechnology company focused on developing breakthrough opioid-free pain relieving (analgesic) treatments for chronic pain, today announced that [Roy Clifford Levitt, MD, Founder and Executive Chairman of Adolore](#) will present at the [16th Annual Pain Therapeutics Summit](#) being held November 14-15, 2022 in Washington, DC.

Selected from a broad range of currently ongoing NIH/NINDS HEAL Programs for pain treatment, Adolore was invited to present at this conference as one of the four novel approaches to treating chronic pain, during the Tuesday morning NIH-chaired section of the Pain Summit.

Details of the presentations are as follows:

Presentation: *Treating Chronic Pain with Localized Delivery of CA8 Gene Therapy*

Date & Time: Tuesday, November 15th at 8:30 AM ET

As part of this presentation, Dr. Levitt will discuss the mechanism-of-action for carbonic anhydrase-8 variant (CA8*) as a novel non-opioid analgesic drug candidate that activates Kv7 channels, pros and cons of localized peripheral nervous system (PNS) delivery of CA8* using replication defective (rd)HSV gene therapy to produce long-lasting analgesia, and proof-of-concept studies of PNS-targeting CA8* rdHSV-mediated gene therapy for the treatment of chronic pain due to knee osteoarthritis.

Panel Session: *Novel Molecular Targets and Approaches for Pain Therapeutics: Will Benefit Overcome Risk?*

Date & Time: Tuesday, November 15th at 10:30 AM ET

Topic Summary: To date, the success rates for novel pain therapeutics across all pain conditions is roughly 2%. In contrast, success rates for all pain therapeutics regardless of novelty but for more specific pain conditions such as nociceptive or neuropathic pain are higher (~10%). Because many non-novel therapeutics have abuse potential, there is general agreement that efforts focused on the development of novel therapeutic entities are critical to achieving the goal of pain management without abuse liability. This panel discussion will focus on the potential promise of novel therapeutic targets along with the associated risks that have plagued the development of new pain therapeutics devoid of abuse potential. All of the panelists in this session will address the benefit: risk evaluation by describing the promise of their new therapeutic target in the context of associated risk and challenges.

For more information, please visit the conference website [here](#).

About Adolore BioTherapeutics, Inc.

Adolore BioTherapeutics, Inc., is a biotechnology company focused on developing novel therapies for the treatment of chronic pain and other nervous system conditions and disorders. Our best-in-class lead programs are long-acting locally acting gene-therapies that are opioid-free Disease Modifying Anti-Pain therapies (DMAPs) for the treatment of a variety of chronic pain and other conditions.

The Company's two current gene therapy programs are in preclinical development for treatment of patients suffering from erythromelalgia, a life-long heritable chronic pain condition representing an orphan drug disease with no approved therapy, and chronic osteoarthritis knee pain, affecting a large number of patients that is often treated with opioids due to the lack of alternatives, thus contributing to the ongoing opioid crisis.

For more information, visit adolore.com.

Investor Relations Contact

JTC Team, LLC

Jenene Thomas

833-475-8247

adolore@jtcir.com